

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>El-Hibri Fuad</u> (Last) (First) (Middle) 400 PROFESSIONAL DRIVE, SUITE 400 (Street) GAITHERSBURG MD 20879 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [EBS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;">Chairman</p>
	3. Date of Earliest Transaction (Month/Day/Year) 05/23/2016	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/23/2016		M ⁽¹⁾		20,000	A	\$15.91	1,719,073	D	
Common Stock	05/23/2016		S ⁽¹⁾		20,000	D	\$42.76 ⁽²⁾	1,699,073	D	
Common Stock	05/23/2016		S ⁽¹⁾		25,000	D	\$42.5	1,674,073	D	
Common Stock	05/24/2016		M ⁽¹⁾		20,000	A	\$15.91	1,694,073	D	
Common Stock	05/24/2016		S ⁽¹⁾		20,000	D	\$42.26 ⁽³⁾	1,674,073	D	
Common Stock	05/25/2016		M ⁽¹⁾		20,000	A	\$15.91	1,694,073	D	
Common Stock	05/25/2016		S ⁽¹⁾		20,000	D	\$42.57 ⁽⁴⁾	1,674,073	D	
Common Stock								2,350,331 ⁽⁵⁾	I	By Intervac, L.L.C.
Common Stock								1,524,155 ⁽⁶⁾	I	By Biovac, L.L.C.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Employee Stock Option (right to buy)	\$15.91	05/23/2016		M ⁽¹⁾			20,000	(7)	03/08/2017	Common Stock	20,000	\$0.00	64,594	D	
Employee Stock Option (right to buy)	\$15.91	05/24/2016		M ⁽¹⁾			20,000	(7)	03/08/2017	Common Stock	20,000	\$0.00	44,594	D	
Employee Stock Option (right to buy)	\$15.91	05/25/2016		M ⁽¹⁾			20,000	(7)	03/08/2017	Common Stock	20,000	\$0.00	24,594	D	

Explanation of Responses:

- The transactions reported herein were effectuated by the Reporting Person pursuant to two separate trading plans adopted on February 29, 2016, each of which are intended to comply with Rule 10b5-1(c) under the Exchange Act.
- The selling price of \$42.76 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from \$42.29 to \$42.85, inclusive. The Reporting Person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- The selling price of \$42.26 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from \$41.58 to \$42.49, inclusive.

